Loading
A phase 1/2 trial of Pembrolizumab, Mesna in colorectal cancer and prostate cancer, run by CuraCell TX AB, now recruiting.
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC is a phase 1/2 interventional study registered as NCT07255664 by CuraCell TX AB, with 12 participants planned, started 2025-11-13 and due to reach its primary completion in 2027-04. Interventions recorded: CC-38, Pembrolizumab, Cyclophosphamid, Interleukin-2, Uromitexan. Conditions listed: Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/